by Annie De Groot | Jun 11, 2020 | Events, Webinars
This webinar has ended, but we invite you to view the recorded recap here. Please join us on July 17, 2020 for our next live webinar, topic TBA! Please extend this invitation to any colleagues or associates you feel would benefit from attending. Participation is...
by Annie De Groot | Nov 6, 2019 | Featured, News
Providence, November 6th 2019 EpiVax announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports EpiVax, Inc (“EpiVax”), a pioneer in immunoinformatics innovation, announces the publication of “Therapeutic administration of...
by Annie De Groot | Feb 26, 2019 | Events
2nd Antigen-Specific Immune Tolerance Drug Development Summit Tuesday, March 26th – Thursday, March 28th, 2019 Wyndham Boston Beacon Hill 5 Blossom Street Boston, Massachusetts 02114 USA Join Dr. Annie De Groot, CEO/CSO EpiVax, at the 2nd Antigen-Specific Immune...
by Annie De Groot | Apr 25, 2017 | Featured, News, Thinking Out Loud -Blog
EpiVax Signs First Commercial License for Tregitope Technology PROVIDENCE, R.I., April 25, 2017 – Providence-based biotechnology company EpiVax, Inc. (“EpiVax”) has licensed its novel immune-modulating technology to an undisclosed global...
by Annie De Groot | Apr 7, 2017 | News
Providence, RI April 7th, 2017 Providence-based biotechnology company EpiVax, Inc. (“EpiVax”) has licensed its novel immune-modulating technology to an unnamed global pharmaceutical company, for use in autoimmune disease and allergy. Tregitopes, pronounced...